SEC Company Response from Wave Life Sciences, Inc. (WVE) (CIK 0001631574) (WVE) — Nov 6, 2015
Wave Life Sciences, Inc. (WVE) (CIK 0001631574)
Date: Nov. 6, 2015 · CIK: 0001631574 · Accession: 0001193125-15-370226
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-207379
Letter
Company Acceleration Request
WAVE Life Sciences Ltd.
8 Cross Street #10-00
PWC Building
Singapore 048424
November 6, 2015
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Suzanne Hayes, Assistant Director
Christina De Rosa
Christian Windsor
Lisa Vanjoske
Joel Parker
Re: WAVE Life Sciences Ltd.
Registration Statement on Form S-1
File No. 333-207379
Acceleration Request
Requested Date: November 10, 2015
Requested Time: 4:00 p.m. Eastern Standard Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, WAVE Life Sciences Ltd. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement to become effective on November 10, 2015, at 4:00 p.m. Eastern Standard Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes each of Matthew J. Gardella and Matthew W. Tikonoff of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, to make such request on its behalf.
In connection with this request, the Registrant acknowledges that:
•
should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please contact Matthew J. Gardella of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (617) 348-1735 with any questions regarding this request.
Very truly yours,
WAVE Life Sciences Ltd.
Show Raw Text
CORRESP 1 filename1.htm Company Acceleration Request WAVE Life Sciences Ltd. 8 Cross Street #10-00 PWC Building Singapore 048424 November 6, 2015 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes, Assistant Director Christina De Rosa Christian Windsor Lisa Vanjoske Joel Parker Re: WAVE Life Sciences Ltd. Registration Statement on Form S-1 File No. 333-207379 Acceleration Request Requested Date: November 10, 2015 Requested Time: 4:00 p.m. Eastern Standard Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, WAVE Life Sciences Ltd. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement to become effective on November 10, 2015, at 4:00 p.m. Eastern Standard Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes each of Matthew J. Gardella and Matthew W. Tikonoff of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, to make such request on its behalf. In connection with this request, the Registrant acknowledges that: • should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Please contact Matthew J. Gardella of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (617) 348-1735 with any questions regarding this request. Very truly yours, WAVE Life Sciences Ltd. By: /s/ Paul B. Bolno, M.D. Name: Paul B. Bolno, M.D. Title: President and Chief Executive Officer cc: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Matthew J. Gardella William C. Hicks Matthew W. Tikonoff Cooley LLP Frank F. Rahmani Nicole Brookshire John T. McKenna